Financials in USD. Standardized financial statements.
A compact view of how Connect Biopharma Holdings Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $64,000 | $26.03M | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -99.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $64,000 | $26.03M | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $58.14M | $48.48M | $69.06M | $119.32M | $98.11M | $29.36M | $16.44M |
| Operating Income? | -$58.07M | -$22.45M | -$69.06M | -$119.32M | -$98.11M | -$30.30M | -$15.99M |
| EBITDA? | -$57.37M | -$21.79M | -$68.34M | -$116.74M | -$201.36M | -$118.21M | -$24.78M |
| Income Before Tax | -$55.28M | -$15.40M | -$61.99M | -$117.79M | -$202.00M | -$119.37M | -$24.46M |
| Income Tax Expense | $197,000 | $223,000 | $120,000 | $298,000 | $266,000 | $0 | $0 |
| Net Income? | -$55.48M | -$15.63M | -$62.11M | -$118.09M | -$202.27M | -$119.37M | -$24.46M |
| EPS? | $-1.00 | $-0.28 | $-1.08 | $-14.50 | $-25.00 | $-14.45 | $-3.02 |
| Diluted EPS? | $-1.00 | $-0.28 | $-1.08 | $-14.50 | $-25.00 | $-14.45 | $-3.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality